Company Overview and News

 
LVL Energy Fund rings opening bell at Colombo Stock Exchange

2018-01-09 lankabusinessonline
LVL Energy Fund Limited (LVEF) rang the opening bell to commence trading and celebrate the listing of its shares at the Colombo Stock Exchange (CSE) today. The listing follows a successful Initial Public Offering by the company, through which it raised Rs. 1.2 billion through a 120 million share issue.

 
LVL Energy Fund announces Rs.1.2bn IPO to fund expansions

2017-12-04 dailymirror.lk
Leading energy company and a subsidiary of Lanka Ventures, the LVL Energy Fund, Limited officially announced a Rs.1.2 billion Initial Public Offering (IPO) yesterday to fund its strategic expansion and growth in the renewable energy sector.

 
LVL Energy Fund to announce Rs1.2bn IPO; largest since 2015

2017-12-04 lankabusinessonline
Dec 04, 2017 (LBO) – A leading energy company and a subsidiary of Lanka Ventures, the LVL Energy Fund is set to announce a 1.2 billion rupees initial public offering on 14th December 2017.

 
Ray Abeywardena appointed as new chairman at CSE

2017-05-04 lankabusinessonline
The Colombo Stock Exchange (CSE) is pleased to announce the appointment of Mr. Ray Abeywardena as the Chairman of the Board of Directors of the CSE with effect from 5th May 2017. Mr. Abeywardena succeeds Mr. Vajira Kulatilaka, who steps down as the Chairman on the conclusion of the customary three year term.

 
Appointment Of Mr Nihal Fonseka As A Member Of The Monetary Board

2016-08-05 bizenglish.adaderana.lk
Mr Anthony Nihal Fonseka has been appointed by His Excellency the President as a Member of the Monetary Board of the Central Bank of Sri Lanka with effect from July 27, 2016 in terms of Section 8(2)(c) of the Monetary Law Act.

 
HNB Grameen shares to be listed in CSE

2016-01-06 lankabusinessonline
Jan 06, 2016 (LBO) – Hatton National Bank’s micro finance arm, HNB Grameen is to list its shares in the Colombo Stock Exchange shortly, Managing Director of HNB, Jonathan Alles said. Alles was spea...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

21h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

21h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...